Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905)

PURPOSE: Antiangiogenic agents combined with chemotherapy have efficacy in the treatment of unresectable malignant pleural mesothelioma (MPM). Cediranib (AstraZeneca, Cheshire, United Kingdom), a vascular endothelial growth factor receptor and platelet-derived growth factor receptor inhibitor, demon...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Tsao, Anne S., Miao, Jieling, Wistuba, Ignacio I., Vogelzang, Nicholas J., Heymach, John V., Fossella, Frank V., Lu, Charles, Velasco, Mario R., Box-Noriega, Brandy, Hueftle, James G., Gadgeel, Shirish, Redman, Mary W., Gandara, David R., Kelly, Karen
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7001793/
https://ncbi.nlm.nih.gov/pubmed/31386610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00269
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados